Welcome to our dedicated page for Breeze Holdings Acquisition news (Ticker: BREZ), a resource for investors and traders seeking the latest updates and insights on Breeze Holdings Acquisition stock.
Breeze Holdings Acquisition Corp. reports SPAC-related corporate developments tied to shareholder votes, material agreements, governance actions and capital-structure disclosures. As a blank-check issuer, its recurring updates center on common stock, rights, warrants, redemption mechanics, security-structure matters and meeting results rather than an operating business segment.
Company news also includes transaction-related communications and financial or regulatory disclosures connected with the SPAC process, while preserving the issuer’s current blank-check company identity.
Breeze Acquisition Corp. II (NASDAQ: BREZU) closed the underwriters’ partial exercise of their over-allotment option for 1,500,000 units at $10.00 per unit, bringing its initial public offering to 14,000,000 units.
Units began trading on May 13, 2026. Each unit includes one ordinary share and one right, with each right converting into one-fifth of a share after an initial business combination.
Breeze Acquisition Corp. II (NASDAQ: BREZU) closed its $125,000,000 initial public offering, selling 12,500,000 units at $10.00 per unit. Units began trading May 13, 2026 on the Nasdaq Global Market.
Each unit includes one ordinary share and one right, with shares and rights to trade as BREZ and BREZR.
Breeze Acquisition Corp. II (Nasdaq:BREZU/BREZ) priced its initial public offering of 12,500,000 units at $10.00 per unit, for gross proceeds of $125 million. Units are expected to begin trading on May 13, 2026.
Each unit includes one ordinary share and one right, with each right converting into one-fifth of a share after a business combination. Underwriters hold a 45-day option for up to 1,875,000 additional units.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) shareholders have approved the business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company focused on vaccines and therapeutic biologics. The special meeting saw 3,128,495 shares represented, with 3,127,474 shares voting in favor of the merger.
The combined entity will be renamed to YD Bio Limited and is expected to trade on the Nasdaq under the ticker symbol "YDES". The transaction is anticipated to close within two weeks, pending customary closing conditions.
Breeze Holdings Acquisition Corp (OTCQX: BRZH) has entered into a definitive agreement to merge with YD Biopharma , a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and exosome-based therapeutics. The combined company, with an estimated enterprise value of nearly $700 million, is expected to be listed on the Nasdaq Capital Market by early 2025.
YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer, and is in the process of acquiring licenses for breast cancer detection technology. The company also specializes in ophthalmology cellular drug development and serves as a clinical testing drug supplier for Novartis.
The transaction, approved by both companies' boards, aims to provide YD Biopharma with capital to expand production and continue development, approval, and launch of new technologies. The combined company will be led by YD Biopharma's current management team.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) has announced its approval to trade on the OTCQX Best Market. The company's common stock and warrants, under tickers 'BRZH' and 'BRZHW' respectively, began trading on August 21, 2024. This update follows the termination of a previously planned business combination with TV Ammo, Inc., as reported in a Form 8-K filing on August 9, 2024.
Breeze's management team is actively pursuing a new business combination transaction and has until December 26, 2024 to complete one, as per SEC requirements. The company plans to provide further updates as progress is made in identifying a potential target company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.